A185750 Stock Overview
Engages in the manufacturing, marketing, and sales of medicines in South Korea and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 0/6 |
| Past Performance | 6/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Chong Kun Dang Pharmaceutical Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩91,300.00 |
| 52 Week High | ₩136,500.00 |
| 52 Week Low | ₩86,000.00 |
| Beta | 0.84 |
| 1 Month Change | -4.20% |
| 3 Month Change | -24.11% |
| 1 Year Change | -27.32% |
| 3 Year Change | -8.89% |
| 5 Year Change | 19.27% |
| Change since IPO | 78.43% |
Recent News & Updates
Is Chong Kun Dang Pharmaceutical (KRX:185750) Using Too Much Debt?
Oct 24
Investors Aren't Buying Chong Kun Dang Pharmaceutical Corp.'s (KRX:185750) Earnings
Sep 27Does Chong Kun Dang Pharmaceutical (KRX:185750) Deserve A Spot On Your Watchlist?
Sep 08Are Investors Undervaluing Chong Kun Dang Pharmaceutical Corp. (KRX:185750) By 41%?
Jul 30Investors Don't See Light At End Of Chong Kun Dang Pharmaceutical Corp.'s (KRX:185750) Tunnel
Jun 12Chong Kun Dang Pharmaceutical (KRX:185750) Seems To Use Debt Rather Sparingly
May 27Recent updates
Is Chong Kun Dang Pharmaceutical (KRX:185750) Using Too Much Debt?
Oct 24Investors Aren't Buying Chong Kun Dang Pharmaceutical Corp.'s (KRX:185750) Earnings
Sep 27Does Chong Kun Dang Pharmaceutical (KRX:185750) Deserve A Spot On Your Watchlist?
Sep 08Are Investors Undervaluing Chong Kun Dang Pharmaceutical Corp. (KRX:185750) By 41%?
Jul 30Investors Don't See Light At End Of Chong Kun Dang Pharmaceutical Corp.'s (KRX:185750) Tunnel
Jun 12Chong Kun Dang Pharmaceutical (KRX:185750) Seems To Use Debt Rather Sparingly
May 27A Look At The Fair Value Of Chong Kun Dang Pharmaceutical Corp. (KRX:185750)
Apr 09Does Chong Kun Dang Pharmaceutical (KRX:185750) Have A Healthy Balance Sheet?
Apr 19Here's Why I Think Chong Kun Dang Pharmaceutical (KRX:185750) Is An Interesting Stock
Apr 05Declining Stock and Solid Fundamentals: Is The Market Wrong About Chong Kun Dang Pharmaceutical Corp. (KRX:185750)?
Mar 09Estimating The Fair Value Of Chong Kun Dang Pharmaceutical Corp. (KRX:185750)
Feb 24The Chong Kun Dang Pharmaceutical (KRX:185750) Share Price Is Up 112% And Shareholders Are Boasting About It
Feb 11Is Chong Kun Dang Pharmaceutical Corp. (KRX:185750) An Attractive Dividend Stock?
Jan 27
Does Chong Kun Dang Pharmaceutical (KRX:185750) Have A Healthy Balance Sheet?
Jan 12With EPS Growth And More, Chong Kun Dang Pharmaceutical (KRX:185750) Is Interesting
Dec 28What Kind Of Shareholders Hold The Majority In Chong Kun Dang Pharmaceutical Corp.'s (KRX:185750) Shares?
Dec 09Could The Market Be Wrong About Chong Kun Dang Pharmaceutical Corp. (KRX:185750) Given Its Attractive Financial Prospects?
Nov 24Shareholder Returns
| A185750 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | 0.8% | 6.1% | 1.9% |
| 1Y | -27.3% | 5.2% | -7.7% |
Return vs Industry: A185750 underperformed the KR Pharmaceuticals industry which returned 5.2% over the past year.
Return vs Market: A185750 underperformed the KR Market which returned -7.7% over the past year.
Price Volatility
| A185750 volatility | |
|---|---|
| A185750 Average Weekly Movement | 4.5% |
| Pharmaceuticals Industry Average Movement | 5.8% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in KR Market | 12.6% |
| 10% least volatile stocks in KR Market | 3.3% |
Stable Share Price: A185750 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A185750's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1941 | 2,276 | Young-Joo Kim | www.ckdpharm.com |
Chong Kun Dang Pharmaceutical Corp. engages in the manufacturing, marketing, and sales of medicines in South Korea and internationally. It provides prescription drugs for anticancer, anti-hypertension, anti-hyperlipidemia, anti-diabetic, and immunosuppressant products; over-the-counter drugs for therapeutic benefits, supplements, and other preventive products; health supplements with preventive benefits, including prebiotics and vitamins with Omega-3; and consumer health products, such as red-ginseng healthy drink, hand sanitizer, and hair color medication, as well as insecticides. The company also exports its products.
Chong Kun Dang Pharmaceutical Corp. Fundamentals Summary
| A185750 fundamental statistics | |
|---|---|
| Market cap | ₩1.17t |
| Earnings (TTM) | ₩189.04b |
| Revenue (TTM) | ₩1.68t |
6.1x
P/E Ratio0.7x
P/S RatioIs A185750 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A185750 income statement (TTM) | |
|---|---|
| Revenue | ₩1.68t |
| Cost of Revenue | ₩1.04t |
| Gross Profit | ₩634.60b |
| Other Expenses | ₩445.56b |
| Earnings | ₩189.04b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 14.97k |
| Gross Margin | 37.87% |
| Net Profit Margin | 11.28% |
| Debt/Equity Ratio | 23.3% |
How did A185750 perform over the long term?
See historical performance and comparisonDividends
1.1%
Current Dividend Yield7%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/19 07:23 |
| End of Day Share Price | 2024/12/19 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Chong Kun Dang Pharmaceutical Corp. is covered by 21 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hyerin Lee | DAOL Investment & Securities Co., Ltd. |
| Jisoo Lee | DAOL Investment & Securities Co., Ltd. |
| null null | DBS Bank Ltd |